By Tim Ryan

At Innovate Hampton Roads, we’re thrilled to spotlight a local hero reshaping global healthcare: ivWatch, a Newport News-based pioneer in IV safety. On June 30, 2025, ivWatch announced a groundbreaking milestone—market authorization under its EU MDR CE Mark for its SmartTouch Sensor to detect iron extravasation events. This approval, covering the UK, Ireland, and Europe, cements ivWatch’s role as a trailblazer in patient safety and showcases Hampton Roads as a hub for world-class innovation.

For the uninitiated, ivWatch’s technology is a game-changer. Its FDA-cleared and CE-marked SmartTouch Sensor uses advanced light-based monitoring to catch IV leaks in real time, preventing severe complications like scarring, nerve damage, or worse. The recent EU approval expands its reach to monitor iron infusions, critical for treating anemia in maternity, oncology, and geriatric care. With 35% of reproductive-age women facing iron deficiency, and IV infusions proving effective in 68% of cases where oral supplements fail, ivWatch’s tech is a lifeline for millions.

The impact is already evident. At Frimley Health NHS Foundation Trust in the UK, vascular access specialist Andrew Barton trialed ivWatch’s sensor, slashing extravasation injuries by 100%. “We went from 2-3 extravasations a week to zero,” Barton shared, noting permanent skin staining and psychological harm avoided. His unit now uses ivWatch as a standard of care, with the tech expanding into maternity wards. Barton’s work, including authoring the NIVAS Infiltration and Extravasation Toolkit, underscores the global ripple effect of ivWatch’s innovation.

This isn’t ivWatch’s first rodeo. Since its founding in 2010, the company has racked up 69 patents, earned FDA clearance for its SmartTouch Sensor in 2024, and even pivoted to produce NIOSH-approved N95 respirators during the pandemic. Recognized by Fast Company, Inc., and Modern Healthcare in 2024, ivWatch also clinched Virginia’s “Coolest Thing Made” award and placed Top 3 in the global Startup World Cup. Backed by 757 Angels, ivWatch employs its staff locally, fueling our region’s economy.

For Hampton Roads, ivWatch’s success is our success. It proves our region can nurture startups that solve global problems, attracting talent, investment, and prestige. Entrepreneurs and innovators, take note: ivWatch’s journey from a Newport News lab to the NIVAS conference stage in Bristol (July 1-2, 2025) shows what’s possible with grit and vision. Programs like 757 Collab and REaKTOR are here to help you follow suit.

As ivWatch continues to save lives and elevate patient care, it’s a beacon for what’s next in Hampton Roads. Stay inspired, get involved, and let’s keep pushing the boundaries of what’s possible—right here at home.

Don’t miss out on key business events, local success stories, and expert insights—subscribe to This Week in 757 and stay ahead in Hampton Roads’ innovation and business community. https://bit.ly/twi757newsletter